Edition:
India

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

133.31USD
20 Jul 2018
Change (% chg)

$-2.22 (-1.64%)
Prev Close
$135.53
Open
$135.31
Day's High
$136.23
Day's Low
$133.30
Volume
191,945
Avg. Vol
489,795
52-wk High
$176.44
52-wk Low
$35.26

Chart for

About

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne... (more)

Overall

Beta: 1.28
Market Cap(Mil.): $3,262.29
Shares Outstanding(Mil.): 64.33
Dividend: --
Yield (%): --

Financials

Sarepta shares soar as Duchenne gene therapy shows promise

Sarepta Therapeutics' shares jumped 60 percent on Tuesday after promising results from a gene therapy study positioned the specialty drugmaker as a potential leader in the market for Duchenne muscular dystrophy (DMD) treatments.

19 Jun 2018

BRIEF-Sarepta And Invitae Expand Partnership To Advance Clinical Research In Duchenne Muscular Dystrophy

* SAREPTA AND INVITAE EXPAND PARTNERSHIP TO ADVANCE CLINICAL RESEARCH IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage:

07 May 2018

BRIEF-Sarepta Therapeutics Reports Q1 Loss Per Share Of $0.28

* SAREPTA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

04 May 2018

BRIEF-Sarepta Therapeutics Announces Partnership With Myonexus Therapeutics

* SAREPTA THERAPEUTICS ANNOUNCES PARTNERSHIP WITH MYONEXUS THERAPEUTICS FOR THE ADVANCEMENT OF MULTIPLE GENE THERAPY PROGRAMS AIMED AT TREATING DISTINCT FORMS OF LIMB-GIRDLE MUSCULAR DYSTROPHIES

04 May 2018

BRIEF-Sarepta Therapeutics Inc Says CEO Douglas Ingram's 2017 Total Compensation Was $56.9 Million

* SAREPTA THERAPEUTICS INC SAYS CEO DOUGLAS INGRAM'S 2017 TOTAL COMPENSATION WAS $56.9 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2I3lSGe) Further company coverage:

27 Apr 2018

BRIEF-Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen

* SAREPTA THERAPEUTICS ANNOUNCES PLAN TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR ACCELERATED APPROVAL OF GOLODIRSEN (SRP-4053) IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO SKIPPING EXON 53

12 Mar 2018

BRIEF-Sarepta Therapeutics Reports Q4 Non-GAAP Loss Per Share $0.28

* SAREPTA THERAPEUTICS ANNOUNCES FOURTH QUARTER 2017 AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

02 Mar 2018

Earnings vs. Estimates